Piqray

Showing 2 posts of 2 posts found.

novartis_outside_1

Novartis’ Piqray combo becomes first Europe-approved therapy for PIK3CA-mutated advanced breast cancer

July 29, 2020
Research and Development, Sales and Marketing Europe, Novartis, Piqray, breast cancer, pharma

The European Commission (EC) has awarded its approval for Novartis’ Piqray (alpelisib) to be made available in combination with fulvestrant …

novartis_side_building

FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer

May 28, 2019
Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma

Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …

Latest content